Long-term Agreements, New Launches, Acquisitions and Strategic Collaborations in Improving Medical Research - Research Report

Long-term Agreements, New Launches, Acquisitions and Strategic Collaborations
    in Improving Medical Research - Research Report Thermo Fisher, Cubist,
                   Agilent, Life Technologies, and Covance

  PR Newswire

  NEW YORK, September 16, 2013

NEW YORK, September 16, 2013 /PRNewswire/ --

Editor Note: For more information about this release, pleas e scroll to bottom

Today, Analysts' Corner announced new research reports highlighting Thermo
Fisher Scientific, Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ:
CBST), Agilent Technologies Inc. (NYSE: A), Life Technologies Corporation
(NASDAQ: LIFE), and Covance Inc. (NYSE: CVD). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Thermo Fisher Scientific, Inc. Research Report

On September 4, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) and
Siemens Healthcare Diagnostics announced the renewal of its long-term
agreement for the use of Thermo Fisher's Procalcitonin (B·R·A·H·M·S PCT™)
technology, available as an automated immunoassay on the Siemens ADVIA Centaur
XP and CP systems in all countries outside the US and China. According to the
Company, the ADVIA Centaur B·R·A·H·M·S PCT™ immunoassay offers clinicians an
integrated solution for accurately diagnosing sepsis and monitoring response
to antibiotic therapy, thereby helping to make improved clinical decisions.
"The continuation of our close collaboration with Siemens significantly
increases the global reach of this critical biomarker, making it available to
a broader patient population," said Marc Tremblay, President of Thermo
Fisher's Clinical Diagnostics division. The Full Research Report on Thermo
Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at: [
http://www.analystscorner.com/r/full_research_report/45ed_TMO ]


Cubist Pharmaceuticals Inc.  Research Report 

On September 11, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that it
has completed the acquisition of Trius Therapeutics, Inc. (Trius) for an
aggregate upfront cash consideration of c.$704 million. "We are very pleased
to complete this acquisition and welcome the Trius team to Cubist," said
Cubist's CEO, Michael Bonney. "Trius is an excellent strategic fit, and its
lead product candidate, tedizolid phosphate, has the potential to be an
important new treatment in the fight against resistant infections. The need
for new treatments to combat drug resistant bacteria is growing, and we will
work diligently to bring this antibiotic product candidate to market in order
to help hospitals and their patients combat these infections. This
transaction is also an important step towards achieving Cubist's Building
Blocks of Growth and continuing our track record of driving shareholder value
over the long term." The Full Research Report on Cubist Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at: [
http://www.analystscorner.com/r/full_research_report/92f2_CBST ]


Agilent Technologies Inc. Research Report 

On September 3, 2013, Agilent Technologies Inc. (Agilent) announced the launch
of its 7000 C Triple Quadrupole Gas Chromatography Mass Spectrometer
(GC/MS/MS). According to the Company, the improved system features new
capabilities, in enhancing system performance, simplifying method optimization
and lowering operating costs, and offers reliability, efficiency, and
ultra-low limits of detection for ultimate confidence in trace-level analysis.
Terry Sheehan, GC/MS Marketing Director at Agilent, commented, "The 7000C
Triple Quadrupole GC/MS/MS, together with Agilent sample-preparation supplies,
enables sensitive, selective and robust techniques for measuring trace
components in complex matrices. In addition, our extensive MRM database of
pesticides and environmental pollutants provides all the information needed
for quick and easy method development." The Full Research Report on Agilent
Technologies Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at: [
http://www.analystscorner.com/r/full_research_report/075e_A ]


Life Technologies Corporation Research Report 

On September 10, 2013, Life Technologies Corp. (Life Technologies) announced
the new Ion AmpliSeq™ Exome Certified Service Provider program, a global
organization of some of the world's top service providers that will sequence
and analyze human exomes in as little as two days. According to the Company,
by the Ion AmpliSeq™ Exome Kit, the Ion Proton™ Sequencer, and the Ion
Reporter™ Software, service providers can sequence two exomes in a single run
-- from DNA to results in just two days, eliminating the need to batch samples
just to make the price of exome sequencing affordable. "As a key partner with
Life Technologies, the Ion AmpliSeq™ Exome Kit provides us with a workflow
that is amenable to large scale variant detection for both the research and
ultimately clinical research laboratories. Sequence data comparisons using a
variety of enrichment and sequencing technologies confirm our commitment to
delivering cost effective data for our customers using the Ion AmpliSeq™ Exome
product," said Dr. Patrice Milos, CEO and President, Claritas Genomics. The
Full Research Report on Life Technologies Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at: [
http://www.analystscorner.com/r/full_research_report/d5de_LIFE ]


Covance Inc. Research Report

On September 4, 2013, Covance Inc. (Covance) and the Indiana Clinical and
Translational Sciences Institute (CTSI) jointly announced a collaboration
agreement to conduct early clinical trials for new medicine on behalf of
biotechnology and pharmaceutical companies. According to the Company, the
partnership will conduct high-quality research in a safe and regulated
environment for sponsors who are looking to recruit both healthy volunteers
and patients for early clinical studies. "The alliance with the Indiana CTSI
will help us provide biopharmaceutical clients with quicker access to patients
in a hospital setting that supports specialized care and monitoring," said Rob
Aspbury, Vice President and General Manager, Global Clinical Pharmacology
Services at Covance. "With quicker access to patients, we can streamline the
drug development process and bring important new medications to patients who
need them." The Full Research Report on Covance Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [ http://www.analystscorner.com/r/full_research_report/5691_CVD



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com .
5.For any urgent concerns or inquiries , please contact us at
    compliance@EquityNewsNetwork.com .
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.


Contact: Joe Thomas; +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.